A series of Pt(ll) complexes with antitumor properties: [1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]PtL2 (meso-l-PtL2) and [erythro-l-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl)ethylenediamine]PtL2, [2L 2C1-, 21-, SO42"; halo F (erythro-8-PtL2), halo = CI (erythro-9-PtL2)] has been modelled by molecular mechanics (MM). The MM calculations were carried out for different isomers and ligand conformations meso-5, meso-X, d,l-5, d,I-X. The compounds with the lowest MM energies have the same geometries as those obtained by X-ray analysis. The calculated MMX energy orders: meso-l-PtL2 < erythro-9-PtL2 < erythro-8-PtL2 for L I-, CI-and SO42-are reverse to the known antitumor activity order-the lowest energy complex (the most stable one)is the one with the highest estrogen activity (meso-l-PtL2). The type of the leaving group (L) does not alter the energy order, which is in agreement with the biological experiments that show a slight dependence of the estrogen properties on the leaving group type.
Introduction
The coordination compounds of Pt(ll) are among the most important antitumor reagents. Cis-Pt(NH3)2CI2(cisplatin) was the first platinum compound tested on a wide scale for cytostatic effects [1] [2] [3] [4] . This compound, however, is toxic and in some cases not selective enough [5] . A new class of Pt(ll) compounds, designed by combining the cytotoxic PtCI2 group (the active moiety in cisplatin) and a diamine ligand with estrogen-receptor affinity has been found [6] [7] [8] [9] . These new complexes retain the estrogen properties of the ligand that binds to the estrogen receptor which is specific for the tumor cell and thus the complexes attack selectively critical areas of the DNA [9] [10] [11] [12] [13] [14] [15] . Such compounds are more selective and less toxic [6] . The synthetic estrogen, hexestrol (HES-nonsteroidal) ( Fig. 1) has been used as a model of a ligand with estrogen-receptor affinity [7] . By exchange of the ethyl side chains with amino groups, HES was transformed into a compound suitable for coordination to Pt(ll) (Fig. 1 ). After this structural modification, however, HES loses its high affinity to the estrogen receptor as well as its marked estrogen activity [17] . To increase the lipophilic character of the diamine, two chlorine atoms have been introduced into 2-and 6-positions of the aromatic rings [18] . The compound thus obtained (meso-1) as well as its dichloroplatinum(ll) complex (meso-l-PtCI2) proved to be "true" estrogens [9] . Transformation of Hexestrol (HES) into a Pt(ll) complex with estrogen activity (meso-1-PtCl2) [7] .
The compounds [meso-l,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylene-diamine] PtL2
(meso-l-PtL2) and [erythro-l-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl) ethylenediamine]PtL2 [2L = 2C1-, 21-, SO42-; halo = F (erythro-8-PtL2), halo = CI (erythro-9-PtL2)] have been found to possess estrogen properties and have been tested as antitumor agents [9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The compounds show different estrogen activity [12] . The type (CI, F, H, OH) and the positions (ortho-, meta-, para-) of the substituents in the aromatic rings strongly influence their estrogen
properties [10, 12, 15] . At the same time the type of the leaving group (CI-, I-, SO42-) was of minor importance for the estrogen activity [18] . The stability of the studied Pt(ll) compounds, used as antitumor agents is important for the transport of the complex to the estrogen receptor. The more stable complex will reach the specific estrogen receptor of the tumor cell in higher concentration [23] .
Recently, we have showed [24, 25] that the thermodynamic stability correlates with the rate of hydrolysis of d,I-and meso-[1,2 bis (2-hydroxyphenyl) ethylenediamine] dichloroplatinum(ll) . Among the studied isomers the lowest energy one, d,I-X shows the highest rate of hydrolysis and highest antitumor activity.
In another theoretical study we have shown that the type and the positions of the ring substituents alter the calculated conformational energies (thermodynamic stabilities) of the studied compounds in agreement with their antitumor activity [26] .
The geometry of the active compounds is also important since it will define the bonding mode to the estrogen receptor. Both factors thermodynamic stability and geometry cannot be taken from crystal structures since these factors for the compounds in solutions may differ substantially. The molecular structure and thermodynamic stability, however, can readily be approached by molecular modelling.
The purpose of the present work is to examine all possible isomers of the compounds mentioned above, using molecular mechanics. Correlations between the calculated MM energies (thermodynamic stabilities) and the known estrogen activity order are expected to be found. Different leaving groups, (CI-, I-, SO42-) were used in the calculations in order to study the influence of the leaving group, L, on the calculated energies and stabilities. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . This approach was successfully applied also for modelling of a number of Pt(ll) compound used as anticancer drugs [37] . We have used the standard MMX (an enhanced version of MMP2) procedure with the parameters collected in its 1988 version [38] (see Appendix) . The calculated MM energies are used to access the relative stability of the studied complexes as suggested elsewhere [39] .
In some cases, namely for cisplatin and its substituted ethylenediamine derivative, MM calculations, which ignore explicitly the electronic factors, gave lower energies for the tetrahedral structures than for the planar ones [24] . To calculate the geometry of the higher energy squareplanar structures by the MM method in such cases we fixed the ligand donor atoms in a plane.
Results and Discussion
The studied complexes are given in Fig. 2 These three compounds were tested and they showed estrogen affinity and activity [18] . The curves obtained are given in Fig.. 
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The same energy order was found for the entire range of studied r values although the energy differences become smaller when moving away from the minima.
From Fig. 4 one may conclude that the shape of all curves is almost independent of the type of the leaving group: the curves are shifted in E and r, but the curvature (a measure of the force constant for Pt-L) is almost the same (MM uses generic values for the three cases).
Complexes with leaving group I. The energy order, thus obtained, meso-l-Ptl < erythro-8-Ptl= < erythro-9-Ptl, is not exactly reverse to the known estrogen activity order [18] , meso-l-Ptlz> erythro-9-Ptl > erythro-8-Ptlz
The complex with the lowest energy (meso-l-Ptl2) has the highest activity. At the same time the energy order for the erythro species: erythro-8-Ptl= < erythro-9-Ptlz does not correlate reversibly with the known activity. However, this energy order was obtained with equal Pt-I bond distances for erythro-8-Ptlz and erythro-9-Ptl=, namely Pt-1=2.670 A (included in the database, see Appendix). 
A survey of the X-ray data in Table shows that erythro-8-Ptl2 has shorter Pt-I distances than those of erythro-9-Ptl=. Since the MM energy of erythro-8-Ptl is slightly lower in value as compared with that of erythro-9-Ptl_ we expected that the energy order erythro-8-Ptl < erythro-9-Ptlz may be reversed when the real distances are taken into account. Thus, the geometry optimization of erythro-8-Ptlz and erythro-9-Ptl was done with available X-ray data for Pt-N, Pt-I bond lengths and I-Pt-I, N-Pt-N bond angles (Table I) [18] .
The other geometry parameters do not differ significantly from those included in the MM database (see Appendix). However, X-ray data are not available for the other complexes in this group: meso-l-Ptlz, erythro-5-Ptl and erythro-7-Ptlz. In these cases parameters close to those for erythro-9-Ptlz were used in the geometry optimization. The reason to use these parameters is that the complexes with unknown structure have CI substituents in 2 positions of the Ph rings as it is in erythro-9-Ptl (with the exception of erythro-5-Ptl).
The complexes were modelled by constraining Pt in the plane of the ligand donor atoms. The calculated bond lengths and bond angles are compared with the experimental values for erythro-8-Ptlz and erythro-9-Ptl in Table I . Within [21, 24] . The results thus obtained follow the trends already obtained for the Ptl complexes. The MMX energy order: meso-l-PtCl < erythro-9-PtCl < erythro-8-PtCI= (which correlates reversibly with the estrogen activity order) was obtained when shorter Pt-L bond lengths (Zv--_0.02 A) are assumed for the erythro-8-PtCl as compared with the erythro-9-PtCI= (as for Ptl= complexes). When optimization was carried out without shortening the Pt-L bond, the order: erythro-8-PtCl= < erythro-9-PtCl= was obtained. The meso-l-PtCl= has always the lowest energy. 5d ) was decided in favour of the Rochon and Melanson structure (Fig. 5a ) by X-ray diffraction [22] :
in (N, N-dimethylenediamine) (sulfato) platinum(ll) complexes with 2 HO molecules, the sulfate ion is a unidentate ligand and another site in the coordination sphere of Pt is occupied by HO.
The antitumor activity of the (ethylenediamine) (sulfato)platinum(ll) complexes is not affected by differences in structures (a) and (d), since in aqueous solutions the sulfato group from the unidentate structure (a)in (ethylenediamine)(sulfato)platinum(ll) complexes is quickly replaced by HO molecules, thus forming the active diaqua(ethylenediamine)platinum(ll)ion (d) [22] .
All complexes in this group were modelled as unidentate monoaqua (ethylenediamine) (sulfato)platinum(ll) complexes (L = SO4 2-and L HO).
The energy order obtained at the minima of the E vs.r(Pt-OSO) correlation curves is: meso-l-PtSO4 < erythro-8-PtSO4 < erythro-9-PtSO4.
Unfortunately, X-ray data for Pt-O bond distances are not available and we do not know how far from the theoretical minimum (rpt. o = 2.1 =) are the experimental bond lengths. In order to obtain the energy order erythro-9-PtSO4 < erythro-8-PtSO4, a shorter (as compared with 2.1 =, obtained at the minimum) Pt-O bond distance (rpt_ o = 1.9 =) in erythro-8-PtSO4 was used.
B. Influence of the type and the positions of the ring substituents on the calculated energies and the estrogen activities (Table II) [26] ).
Meso-l-Ptl2. Meso-l-Ptl2 (four CI substituents in 2-and 6-positions of the aromatic rings) was with the lowest energy (67.56 kcal mol-1) in the studied series of meso isomers. This complex has the highest estrogen activity among all the tested compounds of this group [18] . The calculated energies for all the studied compounds follow the order: meso-1-Ptl2 < erythro-7-Ptl2 < erythro-9-Ptl2 < erythro-8-Ptl2 < erythro-5-Ptl2.
Erythro-9-Ptl and erythro-8-Ptl. Erythro-9-Ptl and erythro-8-Ptl= have also shown estrogen properties and the estrogen activity order: meso-l-Ptl > erythro-9-Ptlz > erythro-8-Ptl [18] follows the energy order we found after taking into account the real bond lengths: meso-l-Ptlz < erythro-9-Ptl < erythro-8-Ptlz. As seen from Table II the calculated energy order is reversed with respect to the estrogen activity order; the complex with the lowest energy has the best estrogen activity (meso-l-PtlJ.
Erythro-8-Ptl2 and erythro-9-Ptl2 have different X substituents: for erythro-8-Ptl2, X = F and for erythro-9-Ptl2, X CI (Fig. 2) . Four other complexes (obtained by exchanging the X and Y positions) were included in the calculations [26] . The calculated MMX energies for erythro-8-Ptl2
and erythro-9-Ptl2 are given in Table II1 .
The results in Table III show that for erythro-8-Ptl2 the lowest energy isomer is the 5-conformer, with X F in 2-position of the axial aromatic ring (MMX = 74.39 kcal mol-, Fig. 2c ). Xray diffraction data reveal that the erythro-8-Ptl2 exists namely as meso isomer in 5 conformation [18] . All other isomers are with higher energies. At the same time for erythro-9-Ptl2 the lowest energy conformer is the % conformer, with X=CI in 2-position of the axial aromatic ring (MMX=71.82 kcal mol-, Fig. 2b ). This is again in full agreement with available X-ray and NMR data which show that erythro-9-Ptl2 exists as meso isomer in :k conformation. These two complexes, erythro-8-Ptl2 (5-conformer) and erythro-9-Ptl2 (:k-conformer) were tested and they show antitumor activity against estrogen positive tumors [18] . If we compare the energies of these two complexes (74.39 and 71.82 kcal mol-) the "preferred" one is erythro-9-Ptl2 (erythro-9-Ptl2 has higher activity than erythro-8-Ptl2). They are both less active (higher energy) as compared with meso-l-Ptl2 (67.56 kcal mol-1). (Fig.2a and Fig. 2d) The results in Table III show also the following trends:
(i) when the X and Y substituents are in an equatorial aromatic ring ( Fig. 2a and 2d ) the exchange of their positions does not influence significantly the calculated MMX energies (compare first and second columns of Table III) .
(ii) when the X and Y substituents are in the axial aromatic ring (Fig. 2b and 2c ) the exchange of their positions increases the calculated energies (compare third and fourth columns of Table III ). Obviously, the "preferred" complexes are those with substituents in the axial ring and CI (F) atom in 2-position of the aromatic ring. In the case of erythro-8-Ptl this is the 5-conformer and in the case of erythro-9-Ptl this is the X-conformer (both were prepared also experimentally).
Erythro-7-Ptl.. Erythro-7-Ptl has also a low energy (MMX =70.08 kcal mol-) as compared with meso-l-Ptl (see the first column of Table II ). This complex, however, has no estrogen activity.
This finding was explained by the absence of OH-substituent in para-position which determines the estrogen properties of the complex. It was accepted that the estrogen receptor of the tumor cell binds the complexes through H-bonds between two OHs in the aromatic rings and binding sites of the receptor [7] . Erythro-5-Pl.. Number of CI atoms in the aromatic rings. The low energy of erythro-7-Ptl (MMX = 70.08 kcal mol-1) is due to the presence of four CI atoms in the aromatic rings as in meso-1-PtI(MMX 67.56 kcal mol-1). With three CI atoms (erythro-9-Ptl) the energy is higher (71.82 kcal mol-1) and with two (erythro-5-Pl) the energy has the highest value (MMX = 77.55 kcal mol-1) (Table II) . For the complexes with X CI the obtained estrogen activity was the highest one. This is in agreement with the assumption that the presence of CI in the aromatic rings increases the lipophilic nature of the compounds improving their binding possibility [18] . This order (third and fourth columns of Table II) is the same as for the meso-5 and meso-X conformers of the studied complexes.
Comparison of the conformational energies of the four isomers meso-& meso-Z, d,l-5 and d,l-Z) for every complex. For meso-1-Ptl (D,L-1-Ptl), erythro-7-Ptl (threo-7-Ptl) and erythro-9-Pl (threo-9-Ptl) the following order was found (1-, 3-and 5 rows in Table II): d,I-X < meso-X meso-6 < d,l-& For erythro-5-Ptl (threo-5-Ptl) again the X-conformers are preferred but the order of the 6-conformers is reverse (2 row in Table II) :
As seen from Table II the d,I-X isomers have lower energies as compared with the meso-X isomers. For erythro-9-Ptl an d,I-X isomer has also been found but its estrogen activity was relatively low [7] . This was explained in terms of two factors: (a) the spatial location of the two N atoms, which was different from that in the meso isomers; (b) the lack of flexibility in the fivemembered chelate ring which hinders the approach of the two Ph rings and O-O distance decrease as is the case in the meso series [7] . It is possible that these complexes, d,I-X, have another mechanism of action (a hydrolysis mechanism). Recently, we have shown that the energy of d,l-3-PtCl, d,I-X, is lower than the energy of the meso-3-PtCl, meso-X, and the rate of hydrolysis and antitumor activity of the first compound are higher than those of meso-3-PtCl [24] .
On the basis of these results, reported elsewhere [24] , the hydrolysis mechanism of action may be assumed for the d,I-X isomer. Obviously, regardless of the mechanism of action, the complexes used as antitumor agents should be thermodynamically stable and should not undergo kinetic substitutions in order to reach the cell unchanged and to attack subsequently the critical area of DNA.
The only compound in this series that preferred the 5 conformation is erythro-8-Ptl:
The calculated energies are in agreement with the X-ray diffraction data, which reveal meso isomer in conformation for erythro-8-Ptl and meso isomer in ;L conformation for erythro-9-Ptl [18] .
Complexes with leaving group CI-. The calculated energies are given in Table II and they follow the   order: meso-l-PtCl < erythro-7-PtCl < erythro-9-PtCl < erythro-8-PtCl < erythro-5-PtCl.
For erythro-8-Ptl and erythro-9-Ptl, four other complexes (obtained after exchanging the X and Y positions) were included in the calculations. The calculated MMX energies for all complexes of erythro-8-Ptl and erythro-9-Ptl are given in Table II1 .
The results for the complexes with leaving group CI show that: (i) meso-X and meso-5 conformers differ only slightly in energy; (ii) the d,I-X isomers have always lower energies as compared with both meso isomers.
Complexes with leaving group S02-. The calculated energies for this group complexes follow the same order (Table II) For explanation of the abbreviations used in this Table see [39] .
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